Core Insights - Yuyue Medical has integrated several health devices, including blood glucose meters, blood pressure monitors, and ventilators, with Ant Group's health management system, allowing automatic synchronization of monitoring data to users' personal health records for better health management [1] - The company has launched AI smart assistants such as "Yuyue Anai Sugar," "Yuyue Breathing Steward," and "Yuyue Blood Pressure Steward," which provide personalized health management advice based on user health data through the Ant Group application [1] - For the period from January to September 2025, Yuyue Medical reported a revenue of 6.545 billion yuan, representing a year-on-year increase of 8.58% (adjusted), while the net profit attributable to shareholders decreased by 4.28% (adjusted) to 1.466 billion yuan [1]

Summary of the Conference Call Company and Industry Overview - The conference call discusses **Ant Group's** health app, **Afu APP**, which aims to become a national health entry point in China, targeting **500 million registered users** and **100 million monthly active users** by **2026** [2][3]. Core Points and Arguments - **User Engagement and Trust**: Afu APP focuses on enhancing user engagement and trust in both consumer and serious medical fields by providing comprehensive health solutions [2][3]. - **Data Utilization**: Ant Group has accumulated **10 years of data**, including **700 million** health insurance code users and **60 million** health insurance members, to train vertical models for precise health services [2][5]. - **Collaboration with Health Insurance**: The company collaborates directly with health insurance to establish data centers, planning to launch **10 local data centers** by **2025** [2][8]. - **Monetization Strategies**: Afu APP's revenue model includes consultation services (approximately **100,000 paid consultations daily**) and drug sales (around **3 million yuan daily**), with future plans to diversify income sources [2][12][15]. - **Product Features**: The app includes features like medical guidance, health goal tracking, and AI consultation, with plans for further upgrades to enhance user experience [3][12]. Additional Important Content - **Data Acquisition Costs**: The cost of acquiring data varies, with initial investments in promoting health insurance codes and purchasing medical data costing around **200 million yuan** annually [10]. - **Technical Challenges**: Current AI models achieve only **60%-70%** accuracy compared to top experts, and regulations prevent AI from independently diagnosing or prescribing [11]. - **Market Positioning**: Ant Group aims to position Afu APP as a leading health service platform, with a revenue target of **100 billion yuan** and a profit goal of **50 billion yuan** by **2026** [3][21]. - **Competitive Landscape**: Compared to competitors like Tencent and JD Health, Afu APP focuses on comprehensive service coverage and high-frequency user engagement, ensuring long-term app retention [19][20]. Conclusion - Ant Group's strategic focus on the Afu APP aims to leverage extensive data and partnerships to create a robust health service platform, addressing both user needs and market demands while navigating regulatory challenges and competition.

国家卫生健康委员会发布的《成人健康体检项目推荐指引（2025年版）》（以下简称《指引》），引 入"健康体检自测问卷"作为体检前导，并将心理健康量表筛查纳入评估体系，推动体检从"标准化套 餐"向"风险导向型"模式转变，为18岁及以上人群提供更科学、更精准的健康体检指导。 《指引》的推出，有助于进一步规范健康体检行为，维护受检者健康权益，推动健康体检行业高质量发 展。 从被动的受检者转变为主动的健康参与者 健康体检自测问卷是《指引》的一大亮点，自测问卷包括个人生活方式、既往病史、家族疾病史等内 容，可引导受检者主动审视自身健康状况，并为后续体检项目推荐和评估提供关键依据。 自测问卷还纳入了焦虑、抑郁等心理量表。在郭清看来，这一举措与聚焦身体疾病的传统认知不同，有 助于推动行业和社会对心理健康同等重视，为全面健康管理建立基础。 此外，《指引》针对心脑血管疾病、常见恶性肿瘤、慢性阻塞性肺疾病、2型糖尿病、骨质疏松、慢性 肾病及认知功能障碍等疾病风险人群，将疾病风险筛查项目划分为优选推荐与可选项目两个层级，当基 本体检提示风险信号时，可依据《指引》建议开展针对性深度风险筛查，弥补基本体检的局限性。 "《指引》具有较强的 ...

《指引》的推出，有助于进一步规范健康体检行为，维护受检者健康权益，推动健康体检行业高质量发 展。 从被动的受检者转变为主动的健康参与者 "《指引》具有较强的权威性、指导性和实操性。"中华医学会健康管理学分会第五届主任委员郭清教授 说。2009年原卫生部出台《健康体检管理暂行规定》，是相关领域早期指导性文件；中华医学会健康管 理学分会2014年发布《健康体检基本项目专家共识》，并于2022年进一步修订。 《指引》在此前基础上，结合疾病谱变化与医学证据更新，进行系统性修改、完善，推动健康体检向健 康管理模式转变。 成人健康体检的关键任务在于促进加强常见疾病管理与重大疾病早诊早治。《指引》中明确的恶性肿瘤 风险涵盖肺癌、肝癌、胃癌等类型，"通过规范体检，这些肿瘤早期发现的可能性较高。"中华医学会肿 瘤学分会主任委员、四川省肿瘤医院院长林桐榆教授介绍。 《指引》有助于推动癌症三级预防理念进一步落地：一级预防关注病因阻断，如通过接种HPV疫苗预防 宫颈癌；二级预防着眼于早诊早治；三级预防则强调规范治疗。"如果在疾病早期通过筛查实现干预， 一定程度上可延缓疾病进展，甚至逆转部分早期病变。"林桐榆说。 "体检机构在告知异常 ...

Group 1 - The core theme of the 20th China Insurance Innovation Forum is "Co-creation and Symbiosis," focusing on how medical services can empower the insurance industry [1][12] - Bai Hua, Chairman and CEO of Yuanhe Medical, emphasized that traditional insurance companies struggle to participate in the medical service process, leading to limited cost control effectiveness [1][12] - Yuanhe Medical holds a 47.8% market share in the non-public medical market in the UK, with 57 hospitals, including 37 general hospitals and 20 specialized hospitals [4][15] Group 2 - The healthcare system in Europe and the US differs significantly from China's, with quality clinical resources held by experts rather than institutions [4][15] - Yuanhe Medical was founded by over 3,000 medical experts who recognized the limitations of medical capabilities and established a managed care model to intervene early in diseases [5][16] - The UK government has transferred public healthcare services to professional institutions, with Yuanhe Medical being the first to manage the public healthcare system [6][17] Group 3 - The essence of insurance is as a payer, and controlling costs is a critical issue; however, the relationship between healthcare providers and insurers often leads to a confrontational dynamic [6][17] - The transition to a 2.0 phase involves controlling disease occurrence rather than relying on patient illness for profit, aligning the values of medical service providers with those of insurance companies [6][18] - Centene Corporation's acquisition of Yuanhe Medical allowed it to enter the European market, focusing on health insurance, which has become a primary direction for the insurance industry in Europe and the US [8][19] Group 4 - In 2024, Yuanhe Medical underwent significant changes with its major shareholder becoming Pure Health, a sovereign fund from the UAE, which also controls a large US healthcare group [9][20] - Pure Health is investing heavily in drug research and development, becoming a significant player in the global biopharmaceutical investment landscape [20][21] - The UAE has established the world's first comprehensive "Longevity Health Management" medical guidelines, reflecting a shift towards preventive health management [21][22] Group 5 - The core of high-end medical insurance lies in cost control, which is challenging for insurance companies that cannot directly engage in medical services [11][22] - Many insurance companies invest heavily in value-added health insurance services, but the effectiveness in improving client health outcomes and reducing claims remains questionable [11][22] - There is a need for deeper collaboration between insurance companies and medical service providers to enhance customer service experiences and better control costs [11][22]

Core Insights - The evolution of smartwatches has positioned them as personal health management hubs, with Huawei's WATCH series leading the industry, particularly highlighted by the launch of the Huawei WATCH 10th Anniversary edition, which serves as both a summary of the past decade and a strategic move for the next ten years [1][14] Product Positioning - The Huawei WATCH 5 marks a significant turning point as the first HarmonyOS AI smartwatch, shifting from passive data recording to active understanding and suggestions, addressing a long-standing challenge in wearable technology [3] - The 10th Anniversary edition further enhances the emotional and technological value integration, emphasizing its significance as a commemorative product [3] Design and Materials - The design features a unique color scheme of Cosmic Blue and Polar White, with a "10YEARS" insignia on the crown, highlighting its commemorative nature [5] - Available in 46mm and 42mm sizes, the watch boasts a titanium alloy body, 904L stainless steel case, and sapphire glass, positioning it among the top tier in the smartwatch market [5] Health Interaction and Dashboard - The new "Health Dashboard" represents a revolutionary change in information organization, structuring complex health data into twelve core health indicators for easier understanding [7] - Users can access animated data explanations and trend analyses with a simple touch, making health metrics more intuitive and perceptible [8] AI Integration - The comprehensive integration of HarmonyOS 6.0 enhances the smartwatch's intelligence, evolving the voice assistant into a "wrist AI butler" capable of providing targeted assistance across various scenarios [10] - The new screen recognition capability allows users to ask natural language questions about displayed data, transforming health management from mere numerical displays to a conversational and understandable advisory system [10] Hardware Advancements - The upgraded X-TAP sensing system integrates PPG, ECG, and pressure sensors in a compact design, improving monitoring speed and accuracy while expanding health monitoring capabilities [12] - Features like ECG, vascular elasticity, fingertip blood oxygen, and hypertension risk assessment signify a shift from "health auxiliary tools" to "long-term health management partners" [12] Market Performance - Over the past decade, Huawei's WATCH series has focused on self-developed technology, continuously expanding the capabilities of smart wearables, leading to a cumulative global shipment of over 200 million devices [12] - According to IDC data, Huawei's wearable device shipments reached 28.6 million units in the first three quarters of 2025, securing the top position in both global and domestic markets, with six consecutive years of leading domestic shipments [12] Strategic Significance - The Huawei WATCH 10th Anniversary edition serves as a pivotal product that summarizes the company's decade-long achievements in health technology, system ecology, and hardware sensing, while also indicating future directions through AI and multi-sensing technology [14] - Priced from 2799 yuan, the watch is set to launch on December 25, attracting interest from potential consumers [14]

Core Viewpoint - SKG is a leading company in the smart wearable health device sector, focusing on integrating professional medical technology into consumer electronics to enhance health management and redefine health experiences [3][4]. Company Overview - SKG has been dedicated to the smart wearable health device field since 2016 and has established itself as a leader in both China and globally [3]. - The company offers a diverse product matrix, including smart soothing wearable devices, post-exercise recovery and shaping devices, smart health watches, and health home products [3]. - SKG's innovative applications of medical technologies such as medium-frequency pulse and transcutaneous electrical nerve stimulation (TENS) have set industry precedents [3]. Market Position - According to Frost & Sullivan, SKG holds the top position in China's smart soothing wearable device market with a projected market share of 21.5% in 2024 [3][11]. - The global smart wearable health device market reached USD 41.7 billion in 2024, expected to grow to USD 79.5 billion by 2029, with a compound annual growth rate (CAGR) of 13.8% [10]. - The Chinese market for smart wearable health devices is projected to grow from RMB 30.9 billion in 2019 to RMB 61.5 billion in 2024, with a CAGR of 14.7% [10]. Financial Performance - SKG's total revenue for 2022, 2023, and 2024 was RMB 904 million, RMB 1.046 billion, and RMB 1.045 billion, respectively, with a net profit increasing from RMB 119 million in 2022 to RMB 136 million in 2024 [7]. - The company's gross profit for the same years was RMB 456 million, RMB 514 million, and RMB 510 million, with gross margins of 50.4%, 49.1%, and 48.9% respectively [7]. - Adjusted net profit figures were RMB 137 million, RMB 123 million, and RMB 126 million for 2022, 2023, and 2024 [8]. Innovation and Patents - As of September 30, 2025, SKG holds 1,501 registered patents globally, including 261 authorized invention patents, and has submitted over 480 pending patent applications [4]. - The company has received international recognition for its innovative designs, including awards such as the Red Dot Design Award and the Hannover Industrial Design Award [4]. Future Plans - SKG plans to use the proceeds from its Hong Kong IPO to enhance its research and development capabilities in health technology, accelerate technological innovation, integrate upstream and downstream resources, and strengthen brand recognition through marketing [11].

在慢病管理上，尹烨给出了简单易行的健康建议：控制体重与血压、多茶少酒、多醋少盐、多水少油、 多动少坐，即使久坐也可通过捏手、抖腿等方式缓解压力。他特别强调，健康管理应从日常细节入手， 比如每天减少1克盐摄入、饭后散步5分钟稳定血糖，这些微小改变能有效降低慢病风险。 对于认知障碍等难题，尹烨分享了前沿研究成果：接种减毒型带状疱疹疫苗可降低20%的认知障碍发生 率，建议40岁以上人群尽早接种；健康大脑需要远离什么？"超加工食品，不要没事熬夜，不要刷垃圾 短视频，希望大家戒烟限酒，避免争强好胜，远离负面情绪，远离恶劣环境，切勿作恶越来越多的事情 告诉我们年轻时候行的善会滋养你，做的恶随着年龄增长了会形成重要的心霾，勿以恶小而为之，勿以 善小而不为。"他说。 专题：财经年会2026：预测与战略暨2025全球财富管理论坛 《财经》年会2026：预测与战略暨2025全球财富管理论坛于2025年12月18-20日在北京举行。华大集团 首席执行官尹烨指出，从人类寿命演进来看，科技进步带来的改变尤为显著。1800年全球人均预期寿命 不足30岁，1949年中国仅为39岁，而如今全球人均寿命已达73岁，中国更是提升至79岁。尹烨表 ...

证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 编号：2025-11 | 投资者关 | □特定对象调研 □分析师会议 | | --- | --- | | 系活动类 | □媒体采访 □业绩说明会 | | 别 | □新闻发布会 路演活动 ☑ | | | □现场参观 | | | 其他（华安证券策略会） | | 参与单位 | 天弘基金 钟颖 李佳豪、工银瑞信基金 李乾宁、民生加银基金 尹 | | 名称及人 涛 | 郝梦娇； | | 员姓名 | 参加华安证券策略会，面向华安证券邀请的投资者，包括 Nature | | | Capital 苗天一、禾晟投资 章孝林、海衍投资 丁威、山西证券 杨 | | | 杰、上海润义投资 陆懿晨、信迹投资 宋文略、绅徽投资 陈彦宁等。 | | 时间 2025 | 年 12 月 18 日 | | 地点 | 路演：天弘基金、工银瑞信基金、民生加银基金公司会议室 | | | 华安证券策略会：陆家嘴富汇大厦 A 座 | | 上市公司 | 董事会秘书 刘泽霖 | | 接待人员 | 投资者关系总监 董丁梦 | | 姓名 | | | | 1、请介绍下公司 ...

Core Insights - The report aims to reveal the health status and potential risks of Shanghai residents through scientific data, emphasizing the importance of health awareness and disease prevention [1][2] Group 1: Health Report Findings - The "Shanghai Health Report" is based on health data from 673,700 individuals who underwent health check-ups at various Aikang centers in Shanghai from April 1, 2024, to March 31, 2025 [1] - Seven health abnormalities, including prostate issues, thyroid nodules, fatty liver, increased BMI, breast nodules, carotid artery abnormalities, and elevated total cholesterol, have shown a continuous upward trend for five consecutive years [1] - The cancer detection rate among the health check-up population is at least 2.20‰, indicating that over two individuals per 1,000 are diagnosed with cancer, surpassing the national average [2] Group 2: Public Health Implications - Chronic diseases are now the primary factors affecting the health and quality of life of Shanghai residents, necessitating a shift from a disease-centered to a health-centered public health system [2] - The report serves as a "compass" for public health policy, a "weather vane" for health industry development, and a "manual" for public self-health management [2] - The CEO of Aikang emphasized the importance of continuous health data tracking to help individuals identify risks earlier and promote the idea that individuals are the primary responsible parties for their health [2]